Interleukin-18 in cardiomyocyte: A novel therapeutic target for attenuating cardiac remodeling. Response

Int J Cardiol. 2018 Sep 1:266:221. doi: 10.1016/j.ijcard.2018.02.049.

Authors

Yoshitaka Okuhara¹, Shunichi Yokoe², Michio Asahi², Haruki Okamura³, Tohru Masuyama¹, Shinichi Hirotani⁴

Affiliations

¹ Cardiovascular Division, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
² Department of Pharmacology, Faculty of Medicine, Osaka Medical College, Osaka, Japan.
³ Laboratory of Tumor Immunology and Cell Therapy, Hyogo College of Medicine, Nishinomiya, Japan.
⁴ Cardiovascular Division, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan. Electronic address: hirotani@hyo-med.ac.jp.

PMID: 29887453
DOI: 10.1016/j.ijcard.2018.02.049

No abstract available

Keywords: Cardiac remodeling; IL-18; Sepsis-induced cardiac dysfunction.

Publication types

Letter
Comment

MeSH terms

Humans
Interleukin-18*
Interleukin-6
Myocytes, Cardiac*
Ventricular Remodeling

Substances

Interleukin-18
Interleukin-6